Health AI Central
Peer-Reviewed Publication
JAMA2025;334(13):1196-1199.October 7, 2025Journal Article

Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias.

Krista Y Chen1, Joseph S Ross2,3, Adam B Cohen4,5, Jason Karlawish6, Esther S Oh7, Ravi Gupta1
1Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
3Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
4Department of Neurology, Yale School of Medicine, New Haven, Connecticut.
5Global Health Mission Area, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland.
6Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia.
7Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.